A Cost-Savings Economic Model for the Canadian Population with Type 2 Diabetes (T2D) Due to Reduction in Mild Hypoglycemia Events for Sodium Glucose Co-Transporter 2 (SGLT-2) Inhibitor Versus Sulfonylurea (SU) Initiation after Metformin

Presentation Number: MON 286
Date of Presentation: April 3rd, 2017

Pendar Farahani*
McMaster University, Hamilton, ON, CANADA

Abstract

Background: Hypoglycemia is associated with lower health-related quality of life and significant costs. However, most economic models do not incorporate the impact of mild hypoglycemia on quality of life and its related costs.

Objective: To calculate cost-savings due to mild hypoglycemia reduction for SGLT-2 inhibitor versus SU initiation after metformin for Canadian population with T2D.

Methods: An economic model was calculated incorporating data from RCTs on SGLT-2 inhibitor versus SU initiation after metformin. Costs per event for mild hypoglycemia were obtained from previous published studies. Data on prevalence of T2D and SU utilization were obtained from Canadian resources.

Results: With assumption of only one mild hypoglycemic event during the first year of SGLT-2 inhibitor versus SU initiation after metformin for the Canadian population with T2D (prevalence data for diabetes for 2015 and SU utilization data for 2013), the total cost from the patients’ perspective would lead to an annual cost-savings of CDN $17,423,517 due to more work productivity and less cost for mild hypoglycemia episodes treatment. Sensitivity analysis resulted in a minimum CDN $3,729,466 cost-savings and a maximum CDN $45,346,140 cost-savings for SGLT-2 inhibitor versus SU initiation after metformin due to mild hypoglycemia reduction for the Canadian population with T2D.

Conclusion: This study illustrates that mild hypoglycemia episodes due to SU utilization for the Canadian population with T2D, which mostly are not reported in real-world clinical settings, can have a significant economic burden on patients.

 

Disclosure: PF: Investigator, Astra Zeneca.